- About bilaterals.org
- Feb-2016: New ISDS platform launched
- Sep-2004: Launch announcement
- Feb-2015: Relaunch of bilaterals.org
- Mar-2013: Relaunch of bilaterals.org
- Jun-2009: Relaunch of bilaterals.org
- Dec-2008: An update from bilaterals.org and logo design contest announcement
- Dec-2006: bilaterals.org in Spanish & French
- Sep-2006: Update from bilaterals.org
- How to participate
- Key issues
- Texts of agreements
Ranbaxy deal may help India’s entry into Japan
Financial Express | June 14, 2008
Ranbaxy deal may help India’s entry into Japan
New Delhi, Jun 13 — The Daiichi Sankyo-Ranbaxy Laboratories deal has come as a shot in the arm for India’s Comprehensive Economic Co-operation Agreement (CECA) negotiations with Japan. Indian pharma companies have been unable to break into Japan, the world’s second largest drug market, due to the country’s stringent sanitary and phytosanitary standards, technical barriers to trade (TBT) and environmental norms.
"The acquisition of Ranbaxy is arecognition of the quality of Indian drug and other pharma products bytheir Japanese counterparts. Before signing the CECA (Comprehensive Economic Cooperation Agreement), we will now aggressively push the case of our pharma sector as well as that of the chemicals, bio-tech and cosmetics sectors to ensure that Japan agrees to opening up their market for these products," a government official told FE.
Since the current Japanese standards on drugs and other pharmaceuticals products are higher than the accepted international standards, it amounts to a non-tariff barrier, the officialofficial added. India will ask Japan to bring their national standards to international levels and also ensure that there is a harmonization of SPS and TBT standards of both countries.
The government is, however, seeing the Ranbaxy deal as a bigger opportunity apart from getting a foothold in the $65 billion pharma market. In a bid to pave the way for the entry of Indian health industry into Japan, New Delhi would also pitch for relaxing the norms for movement of doctors, nurse and other health professionals from India to Japan.
Indian industry sees Japan’s drug approval procedures as stricter and time-consuming. Besides, it is also mandatory to get such products are tested in Japan itself as they do not accept products tested outside that country.
India would now demand that if the US FDA (Food and Drug Administration) has given approval to a drug, Japan must also allow it without any further testing. The government is also keeping a close watch on the deal’s impact on the Indian pharma market and if it would result in costlier drugs entering the country.
News from the movements
23-Feb-2017 S2BPosición de la red S2B sobre la propuesta de la Comisión Europea relativa a un mecanismo multilateral para la solución de controversias entre inversores y Estados (ISDS)
23-Feb-2017 Tele SurOver 280 organizations from around the world sent an open letter to Canadian-Australian mining giant OceanaGold demanding that the company adhere to an earlier ruling that ordered the company to pay the government of El Salvador US$8 million
20-Feb-2017 S2BGlobalisation is at a dangerous crossroads. One path leads to regained policy-space for governments to address climate change, inequality and other pressing issues of our times. The other leads to more rights for corporations to bully decision-makers.
18-Feb-2017 Le DauphinéAlors que le CETA vient d’être ratifié par le Parlement européen, Grenoble organise samedi, après Barcelone, les 2e Rencontres paneuropéennes des villes contre TAFTA - CETA – TISA,
17-Feb-2017 bilaterals.orgEl Coordinador de la Coalición nacional senegalesa “No a los AAE” nos habla de dos proyectos de libre comercio en relación con África: los Acuerdos de asociación económica y la Zona continental de libre comercio
16-Feb-2017 Une Seule Planète
Mouvement citoyens et pouvoirs locaux : quelle alliance pour construire les alternatives aux accords de libre-échange ?La logique des accords de libre-échange est celle d’une croissance infinie des richesses, d’une nature inépuisable d’une capacité exponentielle de l’Humanité à mobiliser le génie scientifique nécessaire pour minimiser les externalités sociales ou environnementales.
15-Feb-2017 RTThe European Parliament has approved a landmark free trade deal between the EU and Canada. Hundreds gathered in Strasbourg, France to protest the Comprehensive Economic and Trade Agreement (CETA).
13-Feb-2017 We Move EuropeEste es un momento crucial para bloquear el CETA. Los eurodiputados tienen una última oportunidad de pararlo el miércoles… ¡pero la votación será reñida! Dile a los eurodiputados que no queremos peligrosos tratados en nuestras vidas.
bilaterals.org is a collaborative space to share information and support movements struggling against bilateral trade and investment deals which serve corporations, not people. Multilingual. Global. No one owns it. Open publishing. Get involved.